MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

MDT

87.86

-1.21%ā†“

VEEV

221.66

-2.12%ā†“

A

109.71

-5.41%ā†“

HQY

82.88

-6.59%ā†“

PDCO

31.2

-0.22%ā†“

Search

OPKO Health Inc

Gesloten

SectorGezondheidszorg

1.57 -4.85

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

1.56

Max

1.65

Belangrijke statistieken

By Trading Economics

Inkomsten

-11M

14M

Verkoop

10M

184M

EPS

0.01

Winstmarge

7.638

Werknemers

2,997

EBITDA

-17M

73M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+55.15% upside

Dividenden

By Dow Jones

Volgende Winsten

6 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-2.7B

1.1B

Vorige openingsprijs

6.42

Vorige sluitingsprijs

1.57

Nieuwssentiment

By Acuity

35%

65%

122 / 386 Rangschikking in Healthcare

OPKO Health Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 mrt 2025, 22:40 UTC

Acquisities, Fusies, Overnames

Tesla Stock Is Reaching a Breaking Point, Analyst Says. Plus, Vertical Aerospace, OPKO Health, and More. -- Barrons.com

Peer Vergelijking

Prijswijziging

OPKO Health Inc Prognose

Koersdoel

By TipRanks

55.15% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2.56Ā USDĀ  55.15%

Hoogste 3Ā USD

Laagste 2Ā USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor OPKO Health Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

4

Buy

0

Hold

0

Sell

Sentiment

By Acuity

122 / 386 Rangschikking in Gezondheidszorg

Nieuwssentiment

Bullish Bewijs

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Boven gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over OPKO Health Inc

OPKO Health, Inc., a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Spain, Chile, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test. Its Pharmaceutical segment offers Rayaldee to treat secondary hyperparathyroidism in adults with stage 3 or 4 chronic kidney disease, and vitamin D insufficiency. This segment also develops multi-specific immune therapies focused on oncology, infectious diseases, vaccines, and immunology; OPK88004, an orally administered selective androgen receptor modulator; OPK88003, a once-weekly administered peptide for the treatment of type 2 diabetes and related obesity; Somatrogon (hGH-CTP), a once-weekly human growth hormone injection; and Factor VIIa-CTP, a novel long-acting coagulation factor being developed to treat hemophilia. In addition, it develops and commercializes longer-acting proprietary versions of already approved therapeutic proteins; develops and produces specialty APIs; develops, manufactures, markets, and sells pharmaceutical, nutraceutical, veterinary, and ophthalmic products; commercializes food supplements and over the counter products; manufactures and sells products primarily in the generics market; and markets, distributes, and sells pharmaceutical products in a range of indications, including cardiovascular products, vaccines, antibiotics, gastro-intestinal products, hormones, and others. The company also operates pharmaceutical platforms in Ireland, Chile, Spain, and Mexico. The company was founded in 2007 and is headquartered in Miami, Florida.